Comprehensive quantitative and qualitative liquid chromatography-radioisotope-mass spectrometry analysis for safety testing of tolbutamide metabolites without standard samples

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 4024-4036

  Tozuka, Zenzaburo ^a   Aoyama, Shinsuke ^a   Nozawa, Kohei ^a   Akita, Shoji ^a   Oh Hara, Toshinari ^a   Adachi, Yasuhisa ^a   Ninomiya, Shin Ichi ^a  

^a SEKISUI CHEMICAL CO LTD   (Japan)

Author keywords

Chromatogrum; HPLC; Mass Spectrometory; Metabolism; Pharmacokinetics; Radioactivity

Indexed keywords

ALPHA HYDROXYL TOLBUTAMIDE; CARBOXYTOLBUTAMIDE; DESBUTYLTOLBUTAMIDE; DRUG METABOLITE; HYDROXYTOLBUTAMIDE O GLUCURONIDE; OMEGA 1 HYDROXYL TOLBUTAMIDE; OMEGA CARBOXY TOLBUTAMIDE; TOLBUTAMIDE; TOLBUTAMIDEMETA GLUTATHIONE; TOLBUTAMIDEORTHO GLUTATHIONE; TOLYLSULPHOAMINOCARBO GLUTATHIONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG URINE LEVEL; FECES; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY RADIOISOTOPE MASS SPECTROMETRY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE;

EID: 79960136084     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22646     Document Type: Article

References (26)

1. US Food and Drug Administration. 2008. FDA guidance for industry: Safety testing of drug metabolites.
2. International Conference on Harmonization. ICH Harmonized Tripartite Guideline: Guidance on M3 (R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (2009).
3. European Medicines Agency. 2004. Committee for medicinal products for human use. Position paper on nonclinical safety studies to support clinical trials with a single microdose. CPMP/ SWP/ 2599/ 02/ Rev 1.
4. US Food and Drug Administration. 2006. FDA guidance for industry. Exploratory IND studies. Guidance. US Department of Health and Human Services. Washington DC: Food and Drug Administration, Center for Drug Evaluation and Research.
5. Ministry of Health, Labor and Welfare. 2008. Guidance. Microdose clinical studies. Tokyo: Ministry of Health, Labor and Welfare, Pharmaceutical and Medical Safety Bureau.
6. Yamane N, Tozuka Z, Sugiyama Y, Tanimoto T, Yamazaki A, Kumagai Y. 2007. Microdose clinical trial: Quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 858:118-128.
7. Yamazaki A, et al. 2010. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labeled drug and LC-MS/MS. J Clin Pharm Ther 35:169-175.
8. Yamane N, Takami T, Tozuka Z, Sugiyama Y, Yamazaki A, Kumagai Y. 2009. Microdose clinical trial: Quantitative determination of nicardipine and prediction of metabolites in human plasma. Drug Metab Pharmacokinet 24(4):389-403.
9. n measurements for structure determination of FK228 and its metabolites. J Mass Spectrom Soc Jpn 53:89-99.
10. n fragmentation in an electrospray ion trap. J Mass Spectrom 38:793-808.
11. 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of its parent and metabolites in healthy subjects. Clin Pharmacol Ther 88:824-830.
12. 14C-tolbutamide by AMS, 25th JSSX abstract. pp 244.
13. n fragmentation of zotepine, tiaramide and their metabolites. Drug Metab Pharmacokinet. 17:316-339.
14. Tozuka Z, Kaneko H, Shortage T, Bopp M, Nina T, Kawamura A, et al. 2003. New SRM data dependent exclusion (MS)n measurement for structural determination of drug metabolites using LC/ESI/Ion trap MS. Drug Metab Pharmacokinet 18:390- 403.
15. Balani SK, Nagaraja NV, Qian MG, Costa AO, Daniels JS, Yang H, et al. 2006. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 34(3):384-388.
16. Alexander JA, Martina KS, Andreas SA, Andreas L, Dorota TS, Julia K, et al. 2004. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 60:165-171.
17. Thomas RC, Ikeda GJ. 1966. The metabolic fate of TB in man and the rat. J Med Chem 88507-510.
18. McDaniel HG, Podgainy H, Bressler R. 1969 The metabolism tolbutamide in rat liver. J Pharmacol Exp Ther 169:91-97.
19. Myers MJ, Farrell DE, Howard KD, Kawalek JC. 2001. Identification of multiple constitutive and inducible hepatic cytochrome P450 enzymes in market weight swine. Drug Metab Dispos 19:908-915.
20. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. 1988. Tolbutamide hydroxylation by human liver microsomes, kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1144.
21. 14C]tolbutamide by human liver microsomal preparations. Life Sci 13:97-105.
22. Bloomer JC, Klarke SE, Kenery RJ. 1997. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos 25(7):840-844.
23. Bellec G, Dreano Y, Bail JP, Menez JF, Berthou F. 1997. Cytochrome P450 hydroxylation of carbon atoms of the alkyl chain of symmetrical N-nitrosodialkylamines by human liver microsomes. Mutat Res 377(2):199-209.
24. DeRuiter J. 2003. Overview of the antidiabetic agents. Endocrine Pharmacotherapy Module.
25. Robert LH, Jeffrey PJ, Kirk RH, Michael BF, Dennis RK, et al. 1999. Enzymatic determinants of the substrate specificity of CYP2C9. Biochemistry 38(11):3285-3292.
26. Guan X, Davis MR, Tang C, Jochheim CM, Jin L, Baillie TA. 1999. Identification of S-(n-butylcarbamoyl)glutathione, a reactive carbamoylating metabolite of tolbutamide in the rat, and evaluation of its inhibitory effects on glutathione reductase in vitro. Chem Res Toxicol 12:1138-1143.